September 29, 2009 – Mardil Inc. last week at TCT 2009 announced positive interim data from a pilot study investigating the safety and efficacy of its novel cardiac device – BACE (Basal Annuloplasty of the Cardia Externally) – in treating mitral valve regurgitation.

September 29, 2009 – Elixir Medical Corp. last week at TCT 2009 announced positive results from three multicenter first-in-man studies of its novolimus and myolimus-eluting coronary stent systems with durable and bioabsorbable polymers.

Novolimus-Eluting Coronary Stent System With Bioabsorbable Polymer

September 29, 2009 – Boston Scientific Corp. Sept. 25 announced two-year follow-up data from the HORIZONS-AMI trial, is designed to determine the safety and efficacy of the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System compared to bare-metal stenting in patients experiencing an acute myocardial infarction (AMI).

September 29, 2009 – At six months, patients receiving the NEVO Sirolimus-Eluting Coronary Stent reported significantly less chest pain than those receiving the TAXUS Liberte stent, and patients also reported improvements in their overall quality of life.

September 29, 2009 – The United States Court of Appeals for the Federal Circuit last week affirmed the previous ruling of the United States District Court for the Northern District of California that Cook Incorporated does not infringe on Edwards’ patents for endovascular devices to treat aneurysms, Cook officials said.

September 29, 2009 – GE Healthcare said the first clinical use of true integrated Fractional Flow Reserve (FFR) has been implemented at Christus St. Vincent Regional Medical Center in Santa Fe, N.M., to evaluate the severity of lesions in coronary arteries.

September 28, 2009 – New data from the phase III PLATO study showed that ticagrelor (BRILINTA) provided 16 percent reduction of cardiovascular (CV) events (composite of CV death, heart attack and stroke) than clopidogrel (9.02 vs. 10.65 percent) in acute coronary syndromes patients undergoing planned invasive treatment of either PCI or CABG.

September 28, 2009 – Sanofi-aventis announced last week the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion recommending to grant a marketing authorization in the European Union for Multaq (dronedarone 400mg tablets).

September 28, 2009 – Data supporting the long-term safety and effectiveness of renal sympathetic denervation (RDN) using radio-frequency ablation in treating patients with chronic hypertension were presented Sept. 25 at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

September 29, 2009 - Positron Corp., a molecular imaging solutions company focused on nuclear cardiology, will attend the 14th Annual American Society of Nuclear Cardiology (ASNC) annual conference in Minneapolis, Minn. Oct. 1-4, to showcase their newly developed cardiac optimized PET scanner, the Attrius.

Subscribe to
Β© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now